Hennion & Walsh Asset Management, Inc. Bio Xcel Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 40,599 shares of BTAI stock, worth $23,547. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,599
Previous 37,402
8.55%
Holding current value
$23,547
Previous $105,000
51.43%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding BTAI
# of Institutions
78Shares Held
7.26MCall Options Held
101KPut Options Held
205K-
Armistice Capital, LLC New York, NY2.99MShares$1.73 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA970KShares$562,8490.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$255,5970.0% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$154,6970.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA204KShares$118,0960.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $16.3M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...